Thyroid Autoimmunity Does Not Define Cardiometabolic or Androgenic Profiles in Women with PCOS

Overview

This study investigates the relationship between thyroid autoimmunity and cardiometabolic or androgenic severity in women with polycystic ovary syndrome (PCOS). Findings indicate that thyroid autoimmunity does not distinguish a metabolically or androgenically severe phenotype in this population.

Background

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among women of reproductive age, often associated with metabolic dysfunctions such as insulin resistance and dyslipidemia. Thyroid autoimmunity (TAI) is frequently observed in women with PCOS, raising questions about its potential role in identifying high-risk subgroups. Understanding the implications of TAI in PCOS is crucial for developing targeted management strategies and improving patient outcomes.

Data Highlights

No significant associations were found between thyroid autoimmunity and cardiometabolic outcomes in women with PCOS.

Key Findings

• TAI_A was not significantly associated with the primary outcome (TG/HDL >3.5) (OR 0.77, 95% CI 0.21–1.67).
• No notable associations were found for secondary outcomes including non-HDL-C ≥130 mg/dL (OR 1.09, 95% CI 0.61–1.76).
• Impaired glucose tolerance on OGTT showed no significant association with TAI (OR 1.27, 95% CI 0.63–2.18).
• Findings were consistent across various definitions of TAI and sensitivity analyses.
• Thyroid-stimulating hormone levels differed between TAI-positive and TAI-negative women, but no significant androgenic or cardiometabolic variables remained after correction for false discovery rate.

Clinical Implications

The absence of a link between thyroid autoimmunity and increased cardiometabolic or androgenic severity in women with PCOS suggests that routine screening for TAI may not be necessary for risk stratification. Clinicians should focus on established metabolic risk factors when managing PCOS.

Conclusion

Thyroid autoimmunity does not appear to define a high-risk metabolic or androgenic phenotype in women with PCOS, highlighting the need for further longitudinal studies to explore its long-term effects.

References

1. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Cytokine Profiling Across Diverse Populations Indicates Immune Dysregulation Rather Than Chronic Inflammation in Polycystic Ovary Syndrome
2. European Journal of Preventive Cardiology, 2023 -- Atherosclerosis risk in women with polycystic ovarian syndrome: it’s not just the comorbidities
3. European Journal of Preventive Cardiology, 2023 -- Nonobese young females with polycystic ovary syndrome are at high risk for long-term cardiovascular disease
4. European Journal of Preventive Cardiology, 2023 -- Addressing Polycystic Ovary Syndrome to Mitigate Cardiovascular Disease Risk
5. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
6. MDPI, 2023 -- Prevalence and Levels of Thyroid Autoantibodies in Polycystic Ovary Syndrome—Impact of TSH- and BMI-Matched Comparisons: A Systematic Review and Meta-Analysis
7. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
8. Prevalence and Levels of Thyroid Autoantibodies in Polycystic Ovary Syndrome—Impact of TSH- and BMI-Matched Comparisons: A Systematic Review and Meta-Analysis | MDPI
9. Hypothyroidism: playing the cardiometabolic risk concerto | Thyroid Research | Springer Nature Link